Does Rifampin Affect Tigecycline Levels?
Rifampin induces CYP3A4 enzymes, which metabolize tigecycline. This interaction lowers tigecycline plasma concentrations by about 50-60%, potentially reducing its efficacy against infections like complicated skin/skin structure infections or intra-abdominal infections.[1][2]
Should Dosage Be Adjusted?
Yes, increase tigecycline dosage when co-administered with rifampin. The manufacturer recommends doubling the maintenance dose from 50 mg IV every 12 hours to 100 mg IV every 12 hours. The loading dose (100 mg IV) stays the same.[3][4]
How Strong Is the Evidence?
Data come from pharmacokinetic studies in healthy volunteers showing AUC reductions with concurrent use. Clinical trials are limited, so monitor patients closely for treatment failure, especially in severe infections. No routine therapeutic drug monitoring exists for tigecycline.[1][5]
What Other Factors Influence Adjustment?
- Renal/Hepatic Impairment: Tigecycline needs no adjustment for these alone, but rifampin adds complexity—assess overall organ function.
- Patient Population: Higher risk in critically ill patients or those with multidrug-resistant infections; consider alternatives if possible.
- Duration: Rifampin induction peaks in 3-5 days, so adjust tigecycline early in combination therapy.[2][4]
Are There Safer Alternatives?
Switch to non-CYP3A4-metabolized antibiotics like colistin or aminoglycosides for rifampin combos, depending on pathogen susceptibility. Rifampin boosts some drugs (e.g., fusidic acid) but antagonizes others—test synergy in vitro.[5]
Key Warnings and Monitoring
Tigecycline carries black-box warnings for increased mortality in non-ventilator hospital-acquired pneumonia and pancreatitis risk. With rifampin, watch for subtherapeutic levels leading to resistance. Consult infectious disease specialists for personalized regimens.[3]
Sources:
[1]: FDA Tigecycline Label
[2]: Drug Interaction Study (PubMed)
[3]: Tygacil Prescribing Information
[4]: Lexicomp Interaction Checker
[5]: IDSA Guidelines on Resistant Infections